Analysis of Intrinsic Breast Cancer Subtypes: The Clinical Utility of Epigenetic Biomarkers and TP53 Mutation Status in Triple-Negative Cases

This study aimed at analyzing the DNA methylation pattern and TP53 mutation status of intrinsic breast cancer (BC) subtypes for improved characterization and survival prediction. DNA methylation of 17 genes was tested by methylation-specific PCR in 116 non-familial BRCA mutation-negative BC and 29 control noncancerous cases. At least one gene methylation was detected in all BC specimens and a 10-gene panel statistically significantly separated tumors from noncancerous breast tissues. Methylation of FILIP1L and MT1E was predominant in triple-negative (TN) BC, while other BC subtypes were characterized by RASSF1, PRKCB, MT1G, APC, and RUNX3 hypermethylation. TP53 mutation (TP53-mut) was found in 38% of sequenced samples and mainly affected TN BC cases (87%). Cox analysis revealed that TN status, age at diagnosis, and RUNX3 methylation are independent prognostic factors for overall survival (OS) in BC. The combinations of methylated biomarkers, RUNX3 with MT1E or FILIP1L, were also predictive for shorter OS, whereas methylated FILIP1L was predictive of a poor outcome in the TP53-mut subgroup. Therefore, DNA methylation patterns of specific genes significantly separate BC from noncancerous breast tissues and distinguishes TN cases from non-TN BC, whereas the combination of two-to-three epigenetic biomarkers can be an informative tool for BC outcome predictions.

[1]  F. Jankevicius,et al.  Promoter Methylation of PRKCB, ADAMTS12, and NAALAD2 Is Specific to Prostate Cancer and Predicts Biochemical Disease Recurrence , 2021, International journal of molecular sciences.

[2]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[3]  Sheng Li,et al.  A DNA Methylation-Based Panel for the Prognosis and Diagnosis of Patients With Breast Cancer and Its Mechanisms , 2020, Frontiers in Molecular Biosciences.

[4]  X. Bian,et al.  Triple-negative breast cancer molecular subtyping and treatment progress , 2020, Breast Cancer Research.

[5]  J. Jackson,et al.  TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines. , 2020, Trends in cancer.

[6]  F. Jankevicius,et al.  DNA methylation of metallothionein genes is associated with the clinical features of renal cell carcinoma. , 2019, Oncology reports.

[7]  Zhenzhen Zhang,et al.  Association of p53 expression with poor prognosis in patients with triple-negative breast invasive ductal carcinoma , 2019, Medicine.

[8]  M. Esteller,et al.  A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients , 2019, Clinical Epigenetics.

[9]  Eric P. Winer,et al.  Breast Cancer Treatment: A Review , 2019, JAMA.

[10]  R. Trojanec,et al.  Genetic Markers in Triple‐Negative Breast Cancer , 2018, Clinical breast cancer.

[11]  Ioana Berindan-Neagoe,et al.  The Epigenetics of Triple-Negative and Basal-Like Breast Cancer: Current Knowledge , 2018, Journal of breast cancer.

[12]  E. Grzybowska,et al.  TP53 mutations and SNPs as prognostic and predictive factors in patients with breast cancer. , 2018, Oncology letters.

[13]  J. McCarthy,et al.  Advances in the systemic treatment of triple-negative breast cancer. , 2018, Current oncology.

[14]  M. Duffy,et al.  Mutant p53 in breast cancer: potential as a therapeutic target and biomarker , 2018, Breast Cancer Research and Treatment.

[15]  Gregory P. Way,et al.  Deconvolution of DNA methylation identifies differentially methylated gene regions on 1p36 across breast cancer subtypes , 2017, Scientific Reports.

[16]  Yun-wei Han,et al.  An early biomarker and potential therapeutic target of RUNX 3 hypermethylation in breast cancer, a system review and meta-analysis , 2016, Oncotarget.

[17]  P. Hainaut,et al.  Somatic TP53 Mutations in the Era of Genome Sequencing. , 2016, Cold Spring Harbor perspectives in medicine.

[18]  S. Libutti,et al.  Reduced expression of FILIP1L, a novel WNT pathway inhibitor, is associated with poor survival, progression and chemoresistance in ovarian cancer , 2016, Oncotarget.

[19]  Dmitriy Sonkin,et al.  TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data , 2016, Human mutation.

[20]  Rodney J Scott,et al.  Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value , 2015, Nature Communications.

[21]  A. Laurinavičius,et al.  Heterogeneity of DNA methylation in multifocal prostate cancer , 2014, Virchows Archiv.

[22]  Shin Jung,et al.  Role of metallothionein 1E in the migration and invasion of human glioma cell lines. , 2012, International journal of oncology.

[23]  C. Cole,et al.  COSMIC: the catalogue of somatic mutations in cancer , 2011, Genome Biology.

[24]  Fang Fang,et al.  Breast Cancer Methylomes Establish an Epigenomic Foundation for Metastasis , 2011, Science Translational Medicine.

[25]  V. Kristensen,et al.  The epigenetics of breast cancer , 2010, Molecular oncology.

[26]  Johan Staaf,et al.  Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns , 2010, Breast Cancer Research.

[27]  S. Lowe,et al.  Tumor suppressive functions of p53. , 2009, Cold Spring Harbor perspectives in biology.

[28]  T. Sørlie,et al.  Full sequencing of TP53 identifies identical mutations within in situ and invasive components in breast cancer suggesting clonal evolution , 2009, Molecular oncology.

[29]  Pang-Kuo Lo,et al.  Epigenomics and breast cancer. , 2008, Pharmacogenomics.

[30]  Masaru Shinozaki,et al.  Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors , 2008, Breast Cancer Research.

[31]  T. Soussi.  p53 alterations in human cancer: more questions than answers , 2007, Oncogene.

[32]  K. Husgafvel‐Pursiainen,et al.  Analysis of TP53 gene mutations in human lung cancer: comparison of capillary electrophoresis single strand conformation polymorphism assay with denaturing gradient gel electrophoresis and direct sequencing. , 2006, Cancer detection and prevention.